Exploring the various aspects of the pathological role of vascular endothelial growth factor (VEGF) in diabetic retinopathy

Pharmacological Research

Volumn 99, Issue , 2015, Pages 137-148

  Behl, Tapan ^a   Kotwani, Anita ^a  

^a UNIVERSITY OF DELHI   (India)

Author keywords

Endothelial progenitor cells (EPCs); Matrix metalloproteinases (MMPs); Oxidative stress; Protein kinase C; VEGF

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; MATRIX METALLOPROTEINASE; PEGAPTANIB; PLACENTAL GROWTH FACTOR; PROTEIN KINASE C; RANIBIZUMAB; VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN E; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; AUTACOID;

CELL PROLIFERATION; CELL SURVIVAL; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SELECTIVITY; ENDOPHTHALMITIS; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME INDUCTION; FOVEAL AVASCULAR ZONE ENLARGEMENT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOXIA; INFLAMMATION; INTRAOCULAR HYPERTENSION; ISCHEMIA; LASER COAGULATION; MACULAR EDEMA; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETINA DETACHMENT; RETINA MACULA HOLE; RETINA MACULOPATHY; RETINA NEOVASCULARIZATION; REVIEW; SYSTEMIC THERAPY; UPREGULATION; UVEITIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; BIOSYNTHESIS; COMPLICATION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; RETINAL NEOVASCULARIZATION; SIGNAL TRANSDUCTION;

ANIMALS; DIABETIC RETINOPATHY; ENDOTHELIAL CELLS; HUMANS; HYPERGLYCEMIA; INFLAMMATION MEDIATORS; MATRIX METALLOPROTEINASES; MODELS, BIOLOGICAL; OXIDATIVE STRESS; PROTEIN KINASE C; RETINAL NEOVASCULARIZATION; SIGNAL TRANSDUCTION; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 84934932422     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2015.05.013     Document Type: Review

References (65)

1. S. Van Dieren, J.W. Beulens, Y.T. van der Schouw, D.E. Grobbee, and B. Neal The global burden of diabetes and its complications: an emerging pandemic Eur. J. Cardiovasc. Prev. Rehabil. 17 2010 S3 S8 10.1097/01.hjr.0000368191.86614.5a
2. T. Behl, N. Kaur, I. Kaur, H. Goel, and R.K. Pandey Mediators involved in diabetic nephropathy: and updated review Asian J. Biochem. Pharm. Res. 4 2014 134 149
3. D.R. Matthews, I.M. Stratton, S.J. Aldington, R.R. Holman, and E.M. Kohner Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69 Arch. Ophthalmol. 122 2004 1631 1640 10.1001/archopht.122.11.1631
4. H.A. Keenan, T. Costacou, J.K. Sun, A. Doria, J. Cavellerano, J. Coney, T.J. Orchard, L.P. Aiello, and G.L. King Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year medalist study Diabetes Care 30 2007 1995 1997
5. M.J. Fowler Microvascular and macrovascular complications of diabetes Clin. Diabetes 26 2008 77 82 10.2337/dc06-2222
6. A.M. Jingi, J.J.N. Noubiap, A. Ellong, J.J.R. Bigna, and C.E. Mvogo Epidemiology and treatment outcomes of diabetic retinopathy in a diabetic population from Cameroon BMC Ophthalmol. 14 2014 19 10.1186/1471-2415-14-19
7. T. Behl, I. Kaur, H. Goel, and R.K. Pandey Diabetic nephropathy and diabetic retinopathy as major health burdens in modern era World J. Pharm. Pharm. Sci. 3 2014 370 387
8. J.S. Penn, A. Madan, R.B. Caldwell, M. Bartoli, R.W. Caldwell, and M.E. Hartnett Vascular endothelial growth factor in eye disease Prog. Retin. Eye Res. 27 2008 331 371 10.1016/j.preteyeres.2008.05.001
9. D.R. Senger Vascular endothelial growth factor: much more than an angiogenesis factor Mol. Biol. Cell 21 2010 377 379 10.1091/mbc.E09-07-0591
10. N. Ferrara Role of vascular endothelial growth factor in regulation of physiological angiogenesis Am. J. Physiol. Cell Physiol. 280 2001 C1358 C1366
11. R. Demir, A. Yaba, and B. Huppertz Vasculogenesis and angiogenesis in the endometrium during menstrual cycle and implantation Acta Histochem. 112 2010 203 214 10.1016/j.acthis.2009.04.004
12. E. Stuttfeld, and K. Ballmer-Hofer Structure and function of VEGF receptors IUBMB Life 61 2009 915 922 10.1002/iub.234
13. K. Holmes, O.L. Roberts, A.M. Thomas, and M.J. Cross Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition Cell Signal. 19 2007 2003 2012
14. H. Huang, J. Shen, and S.A. Vinores Blockade of VEGFR1 and 2 suppresses pathological angiogenesis and vascular leakage in the eye PLoS ONE 6 2011 e21411 10.1371/journal.pone.0021411
15. S. Cébe-Suarez, A. Zehnder-Fjällman, and K. Ballmer-Hofer The role of VEGF receptors in angiogenesis; complex partnerships Cell. Mol. Life Sci. 63 2006 601 615
16. M.J. Flister, A. Wilber, K.L. Hall, C. Iwata, K. Miyazono, R.E. Nisato, M.S. Pepper, D.C. Zawieja, and S. Ran Inflammation induces lymphangiogenesis through up-regulation of VEGFR-3 mediated by NF-kappaB and Prox1 Blood 115 2010 418 429 10.1182/blood-2008-12-196840
17. S. Zacchigna, L. Pattarini, L. Zentilin, S. Moimas, A. Carrer, M. Sinigaglia, N. Arsic, S. Tafuro, G. Sinagra, and M. Giacca Bone marrow cells recruited through the neuropilin-1 receptor promote arterial formation at the sites of adult neoangiogenesis in mice J. Clin. Investig. 118 2008 2062 2075 10.1172/JCI32832
18. F.J. Lin, X. Chen, J. Qin, Y.K. Hong, M.J. Tsai, and S.Y. Tsai Direct transcriptional regulation of neuropilin-2 by COUP-TFII modulates multiple steps in murine lymphatic vessel development J. Clin. Investig. 120 2010 1694 1707 10.1172/JCI40101
19. M. Shibuya Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis Genes Cancer 2 2011 1097 1105 10.1177/1947601911423031
20. T. Matsumoto, and L. Claesson-Welsh VEGF receptor signal transduction Sci. STKE 2001 2001 re21
21. M.J. Cross, J. Dixelius, T. Matsumoto, and L. Claesson-Welsh VEGF-receptor signal transduction Trends Biochem. Sci. 28 2003 488 494
22. X. Li, L. Claesson-Welsh, and M. Shibuya VEGF receptor signal transduction Methods Enzymol. 443 2008 261 284 10.1016/S0076-6879(08)02013-2
23. G. Rusanescu, T. Gotoh, X. Tian, and L.A. Feig Regulation of Ras signaling specificity by protein kinase C Mol. Cell. Biol. 21 2001 2650 2658 10.1128/MCB.21.8.2650-2658.2001
24. S. Mieno, M. Boodhwani, M.P. Robich, R.T. Clements, N.R. Sodha, and F.W. Sellke Effects of diabetes mellitus on VEGF-induced proliferation response in bone marrow derived endothelial progenitor cells J. Card. Surg. 25 2010 618 625 10.1111/j.1540-8191.2010.01086.x
25. S.A. Henry, S.D. Kohlwein, and G.M. Carman Metabolism and regulation of glycerolipids in the yeast Saccharomyces cerevisiae Genetics 190 2012 317 349 10.1534/genetics.111.130286
26. J.M. Berg, J.L. Tymoczko, and L. Stryer Phosphatidate is a common intermediate in the synthesis of phospholipids and triacylglycerols Biochemistry 5th edition 2002 W.H. Freeman & Co., Ltd. New York (Section 26.1)
27. M. Brownlee The pathobiology of diabetic complications Diabetes 54 2005 1615 1625 10.2337/diabetes.54.6.1615
28. J. Varavarovska, R. Stetina, J. Sykora, Z. Rusavy, J. Racek, S. Lacigova, and K. Siala Impact of oxidative stress on diabetes mellitus and inflammatory bowel disease H.V. Panglossi, Frontiers in Antioxidants Research 2006 Nova Science Publishers Inc. US 157 158
29. T. Behl, I. Kaur, H. Goel, and R.K. Pandey PKC activation in the pathogenesis of various diabetic complications Asian J. Biochem. Pharm. Res. 2 2014 232 245
30. P. Geraldes, and G.L. King Activation of protein kinase C isoforms & its impact on diabetic complications Circ. Res. 106 2010 1319 1331 10.1161/circresaha.110.217117
31. B. Poljsak, D. Šuput, and I. Milisav Achieving the balance between ROS and antioxidants: when to use the synthetic antioxidants Oxid. Med. Cell. Longev. 2013 2013 956792 10.1155/2013/956792
32. P. Sharma, A.B. Jha, R.S. Dubey, and M. Pessarakli Reactive oxygen species, oxidative damage, and antioxidative defense mechanism in plants under stressful conditions J. Bot. 2012 2012 217037 10.1155/2012/217037
33. M. Brownlee Biochemistry and molecular cell biology of diabetic complications Nature 414 2001 813 820
34. B.M. Babior, J.D. Lambeth, and W. Nauseef The neutrophil NADPH oxidase Arch. Biochem. Biophys. 397 2002 342 344
35. J.L. Evans, D. Goldfine, B.A. Maddux, and G.M. Grodsky Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes Endocr. Rev. 23 2002 599 622
36. S. Yamagishi Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes Exp. Gerontol. 46 2011 217 224 10.1016/j.exger.2010.11.007
37. A. Klettner, and J. Roider Constitutive and oxidative-stress-induced expression of VEGF in the RPE are differently regulated by different Mitogen-activated protein kinases Graefes Arch. Clin. Exp. Ophthalmol. 247 2009 1487 1492 10.1007/s00417-009-1139-x
38. A.B. El-Remessy, M. Bartoli, D.H. Platt, D. Fulton, and R.B. Caldwell Oxidative stress inactivates VEGF survival signaling in retinal endothelial cells via PI 3-kinase tyrosine nitration J. Cell Sci. 118 2005 243 252 10.1242/jcs.01612
39. M. Frombaum, P. Therond, R. Djelidi, J.L. Beaudeux, D. Bonnefont-Rousselot, and D. Borderie Piceatannol is more effective than resveratrol in restoring endothelial cell dimethylarginine dimethylaminohydrolase expression and activity after high-glucose oxidative stress Free Radic. Res. 45 2011 293 302 10.3109/10715762.2010.527337
40. M.A. Creager, T.F. Lüscher, F. Cosentino, and J.A. Beckman Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I Circulation 108 2003 1527 1532
41. E.R. Pereira, K. Frudd, W. Awad, and L.M. Hendershot Endoplasmic reticulum (ER) stress and hypoxia response pathways interact to potentiate hypoxia-inducible factor 1 (HIF-1) transcriptional activity on targets like vascular endothelial growth factor (VEGF) J. Biol. Chem. 289 2014 3352 3364 10.1074/jbc.M113.507194
42. J.H. Min, H. Yang, M. Ivan, F. Gertler, W.G. Kaelin Jr., and N.P. Pavletich Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling Science 296 2002 1886 1889
43. M.R. Pawlus, L. Wang, and C.-J. Hu STAT3 and HIF1α cooperatively activate HIF1 target genes in MDA-MB-231 and RCC4 cells Oncogene 33 2014 1670 1679 10.1038/onc.2013.115
44. D.S. Boyer, J.J. Hopkins, J. Sorof, and J.S. Ehrlich Anti-vascular endothelial growth factor therapy for diabetic macular edema Ther. Adv. Endocrinol. Metab. 4 2013 151 169 10.1177/2042018813512360
45. T. Asahara, and A. Kawamoto Endothelial progenitor cells for postnatal vasculogenesis Am. J. Physiol. Cell Physiol. 287 2004 C572 C579
46. O.M. Tepper, R.D. Galiano, J.M. Capla, C. Kalka, P.J. Gagne, G.R. Jacobowitz, J.P. Levine, and G.C. Gurtner Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures Circulation 106 2002 2781 2786
47. X. Liu, Y. Li, Y. Liu, Y. Luo, D. Wang, B.H. Annex, and P.J. Goldschmidt-Clermont Endothelial progenitor cells (EPCs) mobilized and activated by neurotrophic factors may contribute to pathologic neovascularization in diabetic retinopathy Am. J. Pathol. 176 2010 504 515 10.2353/ajpath.2010.081152
48. L. Yang, H. Guan, J. He, L. Zeng, Z. Yuan, M. Xu, W. Zhang, X. Wu, and J. Guan VEGF increases the proliferative capacity and eNOS/NO levels of endothelial progenitor cells through the calcineurin/NFAT signalling pathway Cell Biol. Int. 36 2012 21 27 10.1042/CBI20100670
49. R.A. Schulz, and K.E. Yutzey Calcineurin signaling and NFAT activation in cardiovascular and skeletal muscle development Dev. Biol. 266 2004 1 16 10.1016/j.ydbio.2003.10.008
50. C. Napoli, G. Paolisso, A. Casamassimi, M. Al-Omran, M. Barbieri, L. Sommese, T. Infante, and L.J. Ignarro Effects of nitric oxide on cell proliferation: novel insights J. Am. Coll. Cardiol. 62 2013 89 95 10.1016/j.jacc.2013.03.070
51. T. Marumo, V.B. Schini-Kerth, and R. Busse Vascular endothelial growth factor activates nuclear factor-kappaB and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells Diabetes 48 1999 1131 1137
52. I. Kim, S.O. Moon, S.H. Kim, H.J. Kim, Y.S. Koh, and G.Y. Koh Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells J. Biol. Chem. 276 2001 7614 7620
53. K. Noda, S. Nakao, S. Ishida, and T. Ishibashi Leukocyte adhesion molecules in diabetic retinopathy J. Ophthalmol. 2012 2012 279037 10.1155/2012/279037
54. S. Yoshida, A. Yoshida, T. Ishibashi, S.G. Elner, and V.M. Elner Role of MCP-1 and MIP-1alpha in retinal neovascularization during postischemic inflammation in a mouse model of retinal neovascularization J. Leukoc. Biol. 73 2003 137 144 10.1189/jlb.0302117
55. G. Wu, J. Luo, J.S. Rana, R. Laham, F.W. Sellke, and J. Li Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells Cardiovasc. Res. 69 2006 512 519
56. F. Sennlaub, F. Valamanesh, A. Vazquez-Tello, A.M. El-Asrar, D. Checchin, S. Brault, F. Gobeil, M.H. Beauchamp, B. Mwaikambo, Y. Courtois, K. Geboes, D.R. Varma, P. Lachapelle, H. Ong, F. Behar-Cohen, and S. Chemtob Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy Circulation 108 2003 198 204 10.1161/01.CIR.0000080735.93327.00
57. W. Zhang, H. Liu, M. Rojas, R.W. Caldwell, and R.B. Caldwell Anti-inflammatory therapy for diabetic retinopathy Immunotherapy 3 2011 609 628 10.2217/imt.11.24
58. A.S. More, H.M. Kim, G. Khang, T. Hildebrandt, C. Bernlöhr, H. Doods, P.M. Vanhoutte, and D. Wu Des-Arg9-bradykinin causes kinin B1 receptor mediated endothelium-independent contractions in endotoxin-treated porcine coronary arteries Pharmacol. Res. 90 2014 18 24 10.1016/j.phrs.2014.09.001
59. V. Usuelli, and E. La Rocca Novel therapeutic approaches for diabetic nephropathy and retinopathy Pharmacol. Res. 2014 10.1016/j.phrs.2014.10.003 pii: S1043-6618(14)00164-9
60. N. Ferri, and A. Corsini Clinical evidence of statin therapy in non-dyslipidemic disorders Pharmacol. Res. 88 2014 20 30 10.1016/j.phrs.2014.02.003
61. R.P. Verma, and C. Hansch Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs Bioorg. Med. Chem. 15 2007 2223 2268
62. M. Rodrigues, X. Xin, K. Jee, S. Babapoor-Farrokhran, F. Kashiwabuchi, T. Ma, I. Bhutto, S.J. Hassan, Y. Daoud, D. Baranano, S. Solomon, G. Lutty, G.L. Semenza, S. Montaner, and A. Sodhi VEGF secreted by hypoxic Müller cells induces MMP-2 expression and activity in endothelial cells to promote retinal neovascularization in proliferative diabetic retinopathy Diabetes 62 2013 3863 3873 10.2337/db13-0014
63. R.A. Kowluru, Q. Zhong, and J.M. Santos Matrix metalloproteinases in diabetic retinopathy: potential role of MMP-9 Expert Opin. Investig. Drugs 21 2012 797 805
64. V. Usuelli, and E2. La Rocca Novel therapeutic approaches for diabetic nephropathy and retinopathy Pharmacol. Res. 2014 10.1016/j.phrs.2014.10.003 pii: S1043-6618(14)00164-9
65. N. Ferri, and A. Corsini Clinical evidence of statin therapy in non-dyslipidemic disorders Pharmacol. Res. 88 October 2014 20 30